Drug intelligence / Profile preview

ATB226

Development stage: Unknown
Lead developer: AltiBio
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

ATB226 is a small molecule prodrug of tiopronin developed by Altibio. It is designed to improve upon the pharmacokinetic and tolerability profile of tiopronin, offering increased stability, improved bioavailability, reduced gastrointestinal side effects, and potentially better patient compliance. The drug aims for once or twice daily dosing with 24-hour control and is being developed primarily for rare diseases. Its formulation allows for a more stable, odorless product with orphan exclusivity potential[2][1].

Beyond the preview

Go deeper on ATB226.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB226.

Explore the full profile